Tonix Pharmaceuticals Highlights Persistent Opioid Use in Fibromyalgia Patients Despite Guidelines
A Tonix Pharmaceuticals study reveals that 40% of fibromyalgia patients still receive opioid prescriptions, underscoring a gap between clinical practice and evidence-based recommendations and highlighting the need for non-opioid treatments like TONMYA.
Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) presented real-world data at the 2026 American Society of Clinical Psychopharmacology Annual Meeting showing that opioid use remains common among U.S. adults diagnosed with fibromyalgia, despite longstanding treatment guidelines discouraging their use. The findings, based on a retrospective analysis of more than 261,000 patients in the Symphony Health claims database, reveal that approximately 40% of commercially insured, Medicare Advantage, and Medicaid patients with fibromyalgia were prescribed at least one opioid, with tramadol and oxycodone representing the most common prescriptions.
Tonix said the findings underscore a gap between clinical practice and evidence-based recommendations and highlight the need for greater awareness of FDA-approved, non-opioid treatment options, including TONMYA, the company’s recently approved fibromyalgia therapy. TONMYA (cyclobenzaprine HCl sublingual tablets 2.8mg) is the first new treatment for fibromyalgia in more than 15 years.
The data are significant because they quantify the extent of opioid use in a patient population where such prescriptions are generally not recommended due to limited efficacy and risks of addiction and side effects. Fibromyalgia, a chronic pain condition, affects millions of Americans, and the study suggests that many are not receiving guideline-concordant care.
Tonix Pharmaceuticals is a fully-integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. The company’s CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace SymTouch and Tosymra. Tonix is maximizing the science behind TONMYA in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder. In addition, the company’s CNS portfolio includes TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. Tonix is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
The full press release is available at https://ibn.fm/6AtjR. For the latest news and updates relating to TNXP, visit the company’s newsroom at https://ibn.fm/TNXP.